Sangamo Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Sangamo Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sangamo Therapeutics Inc Strategy Report
- Understand Sangamo Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Huntington's disease, Fabry disease, Alzheimer's disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.
Headquarters
United States of America
Address
501 Canal Blvd., Richmond, California, 94084
Website
www.sangamo.com
Telephone
1 510 9706000
No of Employees
405
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SGMO (NASD)
Revenue (2022)
$176.2M
58.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-34.1%
(2022 vs 2021)
Market Cap*
$110.3M
Net Profit Margin (2022)
XYZ
15.3%
(2022 vs 2021)
* As of and is in US$
Sangamo Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Sangamo |
| ZFP Therapeutic Pipeline: | Sangamo Therapeutics |
| SB-525: | Better Therapeutics by Design |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In July, the company entered into an agreement with Chroma Medicine to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. |
| 2022 | Others | In January, the company announced Sanofi to transition its rights and obligations related to SAR445136. |
| 2021 | Others | In December, the company announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136. |
Competitor Comparison
| Key Parameters | Sangamo Therapeutics Inc | Merck & Co Inc | Pfizer Inc | GSK plc | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United States of America |
| City | Richmond | Kenilworth | New York | Brentford | Thousand Oaks |
| State/Province | California | New Jersey | New York | England | California |
| No. of Employees | 405 | 72,000 | 88,000 | 70,212 | 26,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| H. Stewart Parker | Chairman | Executive Board | 2017 | 67 |
| Sandy Macrae, Ph.D. | President; Chief Executive Officer; Director | Executive Board | 2016 | 60 |
| Prathyusha Duraibabu | Chief Financial Officer | Senior Management | 2021 | 44 |
| Mark McClung | Executive Vice President; Chief Operating Officer | Senior Management | 2021 | 60 |
| Whitney Jones | Senior Vice President; Chief People Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward